

Asia-Pacific Oral Anti-Diabetic Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Market Report | 2024-02-17 | 70 pages | Mordor Intelligence

AVAILABLE LICENSES:

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

Report description:

The Asia-Pacific Oral Anti-Diabetic Drug Market size is estimated at USD 25.37 billion in 2024, and is expected to reach USD 29.56 billion by 2029, growing at a CAGR of 3.10% during the forecast period (2024-2029).

COVID-19 caused a gradual rise in demand for diabetes medications in the Asia-Pacific region. Patients with COVID-19 and pre-existing diabetes had blood glucose level changes, according to a study by BeatO in 2021 on 800 people, which finally resulted in a significant demand for cutting-edge medications to treat diabetes. In order to decrease the severe effects of COVID-19, Novo Nordisk has introduced a new social responsibility strategy to fight diabetes and give patients access to low-cost diabetes care in every nation.

Asian nations have seen a sharp rise in the number of people with diabetes over the past few decades, particularly those with type 2. More than 70% of people with diabetes live in developing nations. The Asia-Pacific region is expected to see significant growth as a result of an aging population and an increase in diabetes prevalence, which is mostly caused by increased stress levels, sedentary lifestyles, smoking, and excessive alcohol use that raises blood sugar levels. Also, the production infrastructure of some antidiabetic medicine manufacturers in the area contributed to the market expansion. However, one of the main commercial restraints is thought to be the rising cost of pharmaceuticals.

Biguanides, sulfonylureas, meglitinide, thiazolidinedione (TZD), dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter (SGLT2) inhibitors, glucosidase inhibitors are the main groups of oral antidiabetic drugs.

APAC Oral Anti-Diabetic Drug Market Trends

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Biguanide Segment Occupied the Highest Market Share in the Asia-Pacific Oral Anti-Diabetic Drugs Market in 2022

Biguanide-class medication metformin is used to treat type 2 diabetes. It is prescribed for its "off-label" use in treating patients with illnesses like insulin resistance. Since the advent of metformin therapy, numerous individuals have been successfully treated with this widely available medication with a favorable risk/benefit ratio, and it is recommended by IDF guidelines as a first-line prescription. As a result, metformin-which is administered in 45-50% of all prescriptions and is taken by more than 150 million individuals each year-remains the most frequently prescribed oral antidiabetic medication worldwide. Due to long-term positive experience with metformin use, strong evidence of clinical efficacy, safety, high adherence rate, low cost, widespread availability, and cost-effectiveness, the drug has a sizable market share. According to the World Health Organization, metformin is one of the "medicines that satisfy the priority of healthcare demands of the public."

In recent years, diabetes prevalence has alarmingly increased in the Asia-Pacific region. Diabetes is becoming more prevalent than ever in developing nations like China and India. People with diabetes need to make several adjustments during the day to keep their blood glucose levels within acceptable ranges. Examples include taking oral anti-diabetic medicine or consuming more carbs while keeping an eye on their blood glucose levels. Leading manufacturers are concentrating on technological advancements and the creation of cutting-edge items to capture a sizeable portion of the market.

Owing to the aforementioned factors, the market is expected to grow during the forecast period.

In the Asia-Pacific Oral Anti-Diabetes Medications Market, China and Japan hold more than 25% of the market share.

Due to the rising number of diabetics in Asia-Pacific, China, and Japan have been identified as prospective growth markets. Being a mature market, Japan has a number of difficulties, including weak economic development, an aging population, and rising competition. Patients with type-2 diabetes in this region are increasingly choosing oral anti-diabetics, which has fueled the expansion of the market under study.

The largest market share and the largest contributor to the global diabetes medicine market are both held by China. There are now a lot more companies in the nation making generic medications. The dominant international businesses in the sector under study are also up against fierce regional competition. The Ministry of Health, Labour, and Welfare has designated diabetes as a top healthcare priority. There is a large economic cost associated with the high prevalence of type 2 diabetes. Those with co-morbid conditions like hypertension and hyperlipidemia, as well as those who experience complications, have higher diabetes expenditures. Prices increase as there are more issues. Diabetics can freely see doctors in Japan because of well-organized medical insurance systems that pay for all costs associated with treating diabetes mellitus.

Moreover, self-injection of insulin for therapy has been made lawful and is now covered by insurance. The Japan Association for Diabetes Education and Care runs a few disease management initiatives for the Japanese healthcare system. In terms of diabetes public health policies, Japan is one of the Asia-Pacific region's leaders. These benefits have aided in these items' increased market adoption in Japan.

It is therefore anticipated to drive the category expansion during the forecast period as a result of the aforementioned factors.

APAC Oral Anti-Diabetic Drug Industry Overview

The Asia-Pacific oral anti-diabetes drug market is consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals having a global market presence. In contrast, the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Additional Benefits:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Table of Contents:

1 INTRODUCTION

1.1 Study Assumptions and Market Definition

1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.3 Market Restraints

4.4 Porter's Five Forces Analysis

4.4.1 Bargaining Power of Suppliers

4.4.2 Bargaining Power of Consumers

4.4.3 Threat of New Entrants

4.4.4 Threat of Substitute Products and Services

4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 Oral Anti-diabetic drugs (Value and Volume, 2017 - 2028)

5.1.1 Biguanides

5.1.1.1 Metformin

5.1.2 Alpha-Glucosidase Inhibitors

5.1.2.1 Alpha-Glucosidase Inhibitors

5.1.3 Dopamine D2 receptor agonist

5.1.3.1 Bromocriptin

5.1.4 SGLT-2 inhibitors □

5.1.4.1 Invokana (Canagliflozin)

5.1.4.2 Jardiance (Empagliflozin)

5.1.4.3 Farxiga/Forxiga (Dapagliflozin)

5.1.4.4 Suglat (Ipragliflozin)

5.1.5 DPP-4 inhibitors

5.1.5.1 Onglyza (Saxagliptin)

5.1.5.2 Tradjenta (Linagliptin)

5.1.5.3 Vipidia/Nesina (Alogliptin)

5.1.5.4 Galvus (Vildagliptin)

5.1.6 Sulfonylureas

5.1.6.1 Sulfonylureas

5.1.7 Meglitinides

5.1.7.1 Meglitinides

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.2 Geography

5.2.1 Japan (Value and Volume 2017-2028)

5.2.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

5.2.2 South Korea (Value and Volume 2017-2028)

5.2.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

5.2.3 China (Value and Volume 2017-2028)

5.2.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

5.2.4 India (Value and Volume 2017-2028)

5.2.4.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

5.2.5 Australia (Value and Volume 2017-2028)

5.2.5.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

5.2.6 Vietnam (Value and Volume 2017-2028)

5.2.6.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

5.2.7 Malaysia (Value and Volume 2017-2028)

5.2.7.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

5.2.8 Indonesia (Value and Volume 2017-2028)

5.2.8.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

5.2.9 Philippines (Value and Volume 2017-2028)

5.2.9.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

5.2.10 Thailand (Value and Volume 2017-2028)

5.2.10.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

5.2.11 Rest of Asia-Pacific (Value and Volume 2017-2028)

5.2.11.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

6 MARKET INDICATORS

6.1 Type-1 Diabetic Population (2017 - 2028)

6.2 Type-2 Diabetic Population (2017 - 2028)

7 COMPETITIVE LANDSCAPE

7.1 COMPANY PROFILES

7.1.1 Takeda

7.1.2 Novo Nordisk

7.1.3 Pfizer

7.1.4 Eli Lilly

7.1.5 Janssen Pharmaceuticals

7.1.6 Astellas

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.1.7 Boehringer Ingelheim
- 7.1.8 Merck And Co.
- 7.1.9 AstraZeneca
- 7.1.10 Bristol Myers Squibb
- 7.1.11 Novartis
- 7.1.12 Sanofi

8 MARKET OPPORTUNITIES AND FUTURE TRENDS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Asia-Pacific Oral Anti-Diabetic Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Market Report | 2024-02-17 | 70 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-04"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

